[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A, Mohammad RM: Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Mol Cancer; 2008 Feb 14;7:20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.
  • Elevated expression of anti-apoptotic Bcl-2 family proteins have been linked to a poor survival rate of patients with Follicular Lymphoma (FL).
  • This prompted us to evaluate a very potent non-peptidic Small-Molecule Inhibitor (SMI) targeting Bcl-2 family proteins, Apogossypolone (ApoG2) using follicular small cleaved cell lymphoma cell line (WSU-FSCCL) and cell isolated from lymphoma patients.
  • ApoG2 inhibited the growth of WSU-FSCCL significantly with a 50% growth inhibition of cells (IC50) of 109 nM and decreased cell number of fresh lymphoma cells.
  • In the WSU-FSCCL-SCID xenograft model, ApoG2 showed a significant anti-lymphoma effect, with %ILS of 84% in the intravenous and 63% in intraperitoneal treated mice.
  • These studies suggest that ApoG2 can be an effective therapeutic agent against FL.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, small cleaved-cell, follicular.
  • Genetic Alliance. consumer health - Follicular lymphoma 1.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1984 Feb;44(2):768-71 [6581864.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1277-83 [11948143.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):1019-24 [8473376.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Oct 1;70(1):62-7 [8221615.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1748-55 [7564520.001]
  • [Cites] Cancer Gene Ther. 1995 Sep;2(3):207-12 [8528964.001]
  • [Cites] Nature. 1996 May 23;381(6580):335-41 [8692274.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27886-92 [9346936.001]
  • [Cites] Mol Hum Reprod. 1998 Dec;4(12):1099-109 [9872359.001]
  • [Cites] J Cell Biol. 1999 Jan 25;144(2):281-92 [9922454.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • [Cites] Br J Haematol. 2004 Dec;127(5):519-30 [15566355.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):25-31 [15651174.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):344-54 [15531918.001]
  • [Cites] Oncology (Williston Park). 2005 Feb;19(2):213-28; discussion 228, 233-6, 239 [15770890.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Nursing. 2005 Jul;35(7):56-63; quiz 63-4 [15988223.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):322-31 [16213584.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4143-9 [16896003.001]
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1563-8 [16530831.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2006 Oct;28(8):533-91 [17136234.001]
  • [Cites] Chembiochem. 2007 Jan 2;8(1):113-21 [17139689.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):112-21 [17200714.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):621-9 [17255285.001]
  • [Cites] J Med Chem. 2007 Feb 22;50(4):641-62 [17256834.001]
  • [Cites] N Engl J Med. 2007 Feb 15;356(7):741-2 [17301308.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2226-35 [17404107.001]
  • [Cites] Cancer. 2007 May 15;109(10):2077-82 [17394190.001]
  • [Cites] Leuk Res. 2007 Jun;31(6):859-63 [17224180.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9303-7 [10734071.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(6):480-2 [1394805.001]
  • (PMID = 18275607.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109389; United States / NIGMS NIH HHS / GM / GM058905B; United States / NIGMS NIH HHS / GM / R25 GM058905; United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / P30 CA22453-20
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ PMC2265299
  •  go-up   go-down


2. Jacobsen E, Chen JH, Schurko B, Benson C, Oh WK: Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report. Cases J; 2009;2:7273

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report.
  • An asymptomatic 67-year-old man presented with a left supraclavicular lymph node that enlarged over a 2-month period which was biopsied.
  • Pathologic features were consistent with involvement by metastatic seminoma and follicular lymphoma, follicular pattern, grade 1 (of 3).
  • Staging Positron Emission Tomography/Computed Tomography scans indicated several areas of enlarged lymph nodes.
  • The patient completed chemotherapy with bleomycin, etoposide, and cisplatin chemotherapy.
  • This is the first reported case of metastatic seminoma and follicular lymphoma occurring in the same lymph node.
  • Given the natural history of these two malignancies, if this patient develops recurrent lymphadenopathy, it will be difficult to identify whether the enlarged lymph nodes represent recurrent seminoma or follicular lymphoma without a biopsy of each pathologically enlarged node.
  • Similarly, Fluorodeoxyglucose- Positron Emission Tomography is known to be active in both seminoma and follicular lymphoma, making this scan non-specific in this patient.
  • Finally, this patient had no baseline elevation in any germ cell tumor marker.
  • Thus, serum tumor markers cannot be relied upon as surrogates for response to chemotherapy or as identifiers of relapsed seminoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ Clin Evid. 2007;2007. pii: 1807 [19454048.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):825-37, vii-viii [18954739.001]
  • [Cites] World J Urol. 2004 Apr;22(1):41-6 [15024601.001]
  • [Cites] J Intern Med. 1994 Jul;236(1):91-2 [8021579.001]
  • [Cites] Semin Hematol. 2008 Jul;45(3 Suppl 2):S2-6 [18760706.001]
  • (PMID = 19918516.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769346
  •  go-up   go-down


3. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C: Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res; 2009 Jun 15;15(12):4038-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
  • PURPOSE: To investigate the activity of SAR3419, a novel humanized anti-CD19 antibody (huB4), conjugated to a cytotoxic maytansine derivative N(2)'-deacetyl-N(2)'-(4-mercapto-4-methyl-1-oxopentyl) maytansine, in preclinical xenograft models for non-Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: Antitumor activity of SAR3419 was assessed as a single agent and in comparison with conventional therapies using a subcutaneous model for diffuse large B-cell lymphoma (WSU-DLCL2) and a systemic model for follicular small cleaved cell lymphoma (WSU-FSCCL) in mice with severe combined immune deficiency.
  • RESULTS: Our results showed that in these chemotherapy-resistant models, SAR3419 was more effective than CHOP (cyclophosphamide-Adriamycin-vincristine-prednisone) regimen or rituximab.
  • Only treatment with SAR3419 led to survival of the whole group of animals to the end of the experiment (150-155 days) in both models.
  • Treatment with rituximab resulted in antitumor activity in both models comparable with the low dose of SAR3419.
  • Necropsy and tissue staining in the WSU-FSCCL systemic model revealed that all deaths featured leptomeningeal lymphoma in the control and treated groups.
  • Interestingly, some of the animals that survived to the end of the experiment and seemed healthy at time of euthanasia did show microscopic evidence of lymphoma.
  • CONCLUSIONS: Overall, SAR3419 is a very active immunotoxin in preclinical models for human B-cell lymphoma and holds promise as a novel and well-tolerated therapy in B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Immunoconjugates / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Maytansine / analogs & derivatives. Maytansine / therapeutic use
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Antigens, CD19 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunologic Factors / therapeutic use. Mice. Mice, SCID. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509168.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD19; 0 / Antineoplastic Agents, Phytogenic; 0 / Immunoconjugates; 0 / Immunologic Factors; 0 / N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine; 14083FR882 / Maytansine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


Advertisement
4. Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J: Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. Ann Oncol; 2000 Jan;11(1):115-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
  • Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma were treated by combination chemotherapy with irinotecan hydrochloride (CPT-11) and adriamycin (ADM): CPT-11, 25 mg/m2 on days 1 and 2; ADM, 40 mg/m2 on day 3.
  • Fairly good responses were seen in relapsed B-cell lymphomas (4 of 8 in diffuse large B-cell lymphoma and 2 of 2 in follicular lymphoma grade 1), and substantial responses in T-cell lymphomas (1 of 4 in peripheral T-cell lymphoma and 2 of 7 in adult T-cell leukemia/lymphoma).
  • Combination chemotherapy with a reduced dose CPT-11 and ADM was useful in the treatment of relapsed non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10690400.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; 80168379AG / Doxorubicin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Rohatgi N, LaRocca RV, Bard V, Sethuraman G, Foon KA: Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Am J Hematol; 2002 Jul;70(3):181-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
  • Advanced follicular lymphomas, grades I and II, are indolent tumors but are not considered curable with standard therapy.
  • However, fludarabine-based combination chemotherapy regimens have been associated with significant myelotoxicity.
  • Patients with bulky stage II, stage III, or stage IV follicular lymphoma (grade I or II) were entered on this protocol.
  • Response was assessed after the 3(rd) cycle of fludarabine and after the 4(th), 6(th), and 8(th) cycles of CNOP.
  • The sequential combination of fludarabine and CNOP appears to be active and well tolerated in patients with grade I and II follicular lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Lymphoma, Follicular / drug therapy. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Vidarabine / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12111762.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; MCOP protocol
  •  go-up   go-down


6. Dölken MT, Schüler F, Hirt C, Lorenz G, Hosten N, Dölken G: Multiple osteolytic lesions and testicular involvement at first relapse of follicular lymphoma grade 1 in transformation. Leuk Lymphoma; 2006 Feb;47(2):369-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple osteolytic lesions and testicular involvement at first relapse of follicular lymphoma grade 1 in transformation.
  • A 62-year-old man was initially diagnosed with stage IA follicular lymphoma grade 1 of the left tonsil.
  • Shortly after radiotherapy he rapidly developed multiple painful acroosteolytic lesions and testicular involvement.
  • The histological examination revealed a transformed lymphoma in the testis (DLCL) and follicular lymphoma in the acroosteolytic lesions.
  • The clonal identity of lymphoma cells within the primary biopsy as well as in the two sites at relapse was shown by PCR and nucleotide sequence analysis of the lymphoma clone specific B-cell receptor rearrangement.
  • Chemotherapy with six cycles of CHOP followed by high dose chemotherapy and autologous blood stem cell transplantation led to a complete clinical remission with disappearance of all osteolytic lesions.
  • [MeSH-major] Bone Neoplasms / diagnosis. Lymphoma, Follicular / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Staging. Osteolysis / etiology. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction. Transplantation, Autologous. Treatment Outcome


7. Matsuo T, Ichimura K, Shinagawa K, Yoshino T: Different histopathological types of orbital lymphoma 16 years after systemic follicular lymphoma: immunohistochemical and immunogenetic analyses of two cases. J Clin Exp Hematop; 2008 Apr;48(1):17-24
Genetic Alliance. consumer health - Orbital lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different histopathological types of orbital lymphoma 16 years after systemic follicular lymphoma: immunohistochemical and immunogenetic analyses of two cases.
  • The purpose of this study is to show that the histopathological type of an orbital lymphoma can differ from the systemic follicular lymphoma that precedes it.
  • A 44-year-old man (Patient #1) and a 50-year-old man (Patient #2) presented with generalized lymphadenopathy due to grade 1 follicular lymphoma proven on lymph node biopsy.
  • Patient #1 was followed without treatment for 16 years when he developed a right orbital mass.
  • Patient #2 underwent several courses of combination chemotherapy as well as radiation but relapsed.
  • The second biopsy of the lymph node nine years later showed the same histopathological type of follicular lymphoma.
  • He developed an orbital mass on the right side 16 years after the initial presentation.
  • In Patient #1, excisional biopsy of the orbital masses showed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
  • In Patient #2, biopsy revealed the orbital mass to be T-cell/histiocyte-rich diffuse large B-cell lymphoma.
  • In Patient #1, when comparing the original lymph node biopsy to the orbital biopsy obtained years later, no evidence for clonality was noted by polymerase chain reaction.
  • In Patient #2, the amplification by polymerase chain reaction of the immunoglobulin heavy chain gene rearrangement in the lymph node lesion and the orbital lesion gave rise to a single discrete band with the same DNA sequence except for five nucleotide changes, indicating the same clonality in the presence of genomic changes.
  • In conclusion, orbital lymphomas can occur as a second lymphoma with a different histopathological type in the long-term follow-up of systemic lymphomas.
  • The original and subsequent lymphomatous lesions may or may not share neoplastic cell clonality and all genomics.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Neoplasms, Second Primary / pathology. Orbital Neoplasms / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434689.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Fujiu K, Sakuma H, Shio Y, Suzuki H, Mori M: [A case of non-Hodgkin's lymphoma after chemotherapy for cancer of unknown origin]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1907-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-Hodgkin's lymphoma after chemotherapy for cancer of unknown origin].
  • We present a case of non-Hodgkin's lymphoma after chemotherapy for a cancer of unknown origin.
  • Computed tomography(CT)scans showed a swelling of the superior mediastinal lymph node and a tumor of the right lobe of thyroid gland.
  • Resection of the superior mediastinal lymph node and right hemithyroidectomy were performed.
  • Pathological findings of the lymph node showed adenosquamous cell carcinoma, but no malignant lesion was found in the thyroid gland.
  • Post-operative systemic survey failed to identify the origin of the adenosquamous cell carcinoma.
  • Six courses of chemotherapy consisting of carboplatin and docetaxel were carried out.
  • Seven months later, CT and positron emission tomography revealed swelling of the mediastinal lymph nodes and a tumor in the left abdominal tumor.
  • An open biopsy of the abdominal tumor demonstrated non-Hodgkin's lymphoma, mature B cell type, follicular lymphoma, grade 1.
  • Radiotherapy was done for the malignant lymphoma, and radiochemotherapy for the mediastinal lymph nodes.
  • Seven months later, the patient died of systemic metastases of the adenosquamous cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Combined Modality Therapy. Humans. Male. Tomography, X-Ray Computed. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011340.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Asahi A, Okamoto S, Matsushita H, Hattori Y, Takayama N, Ikeda Y: [Follicular lymphoma in two brothers]. Rinsho Ketsueki; 2001 May;42(5):408-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follicular lymphoma in two brothers].
  • Two brothers, whose parents had a history of exposure to atomic bomb radiation, developed non-Hodgkin's lymphoma.
  • The younger brother, a 48-year-old man, was diagnosed as having follicular small-cleaved cell lymphoma in October, 1996.
  • He had extranodal lymphoma involvement of the right kidney, bone marrow and skin, in addition to generalized lymphadenopathy.
  • He was treated with intermittent COP chemotherapy, and good control of the lymphoma was obtained.
  • The elder brother, aged 50 years, was diagnosed as having follicular mixed cell lymphoma in May, 1998.
  • He also had extranodal lymphoma involvement of the right parotid gland and bone marrow, as well as generalized lymphadenopathy.
  • After one course of CHOP chemotherapy, he developed paresis of the lower legs and was found to have a mass at the Th5-6 vertebrae by CT scan.
  • After four courses of CHOP chemotherapy followed by ESHAP chemotherapy and radiotherapy, he achieved complete remission, and has since been well.
  • Follicular lymphoma occurring among siblings is rare.
  • [MeSH-major] Lymphoma, Follicular / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Family Health. Humans. Male. Middle Aged. Nuclear Warfare. Prednisolone / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11452461.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; COP protocol 2; VAP-cyclo protocol
  • [Number-of-references] 15
  •  go-up   go-down


10. Jacobsen E, Lomo L, Briccetti F, Longtine J, Freedman A: Follicular lymphoma with bilateral testicular and epididymal involvement: case report and review of the literature. Leuk Lymphoma; 2005 Nov;46(11):1663-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma with bilateral testicular and epididymal involvement: case report and review of the literature.
  • Testicular involvement with indolent lymphoma is extremely rare, particularly in the absence of transformation to an aggressive histology.
  • Histologic examination of lymph node, bone marrow, and testicular/epididymal biopsies revealed involvement with grade I follicular lymphoma.
  • The patient was started on chemotherapy with cyclophosphamide, vincristine, prednisone, and rituximab in addition to intrathecal methotrexate and testicular radiation.
  • He is now 6 months into therapy and responding well.
  • A review of the literature demonstrated this to be the first confirmed case of testicular and epididymal involvement with grade I follicular lymphoma.
  • [MeSH-major] Epididymis / pathology. Lymphoma, Follicular / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lymph Nodes / pathology. Lymphatic Irradiation. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236619.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA: High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma; 2001 Nov-Dec;42(6):1255-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
  • The main objectives of this study were to determine the feasibility of administering high doses of cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) every 14-21 days to patients with follicular small cleaved cell lymphoma.
  • For each patient, the treatment was not considered feasible if fewer than four cycles of cyclophosphamide chemotherapy could be administered on schedule (i.e. at least every 29 days) or (1) hospitalization of the patient for longer than three days was necessary for neutropenic fever (38 degrees C) or bacteriologically documented infection in > 50% of the cycles, or (2) grade > or = 2 hemorrhage in association with thrombocytopenia of grade > or = 3 severity occurred in > 50% of the cycles or (3) non-hematologic toxicity (excluding nausea/vomiting and alopecia) of grade > or = 3 occurred in > 50% of cycles.
  • The goal was to have a treatment program feasible in 75% or more of the treated patients.
  • The secondary objectives were to determine the toxicities, the complete and partial response rates, and the time to treatment failure (TTF).
  • The trial also attempted to assess the effectiveness of this treatment program in eradicating Bcl-2 rearrangements by PCR, and to assess complete remission duration in relationship to PCR results in patients who respond to this chemotherapy program.
  • Patients were required to have histologically documented non-Hodgkin's lymphoma of the subtypes follicular, predominantly small cleaved cell (IWF-B) or follicular mixed, (IWF-C).
  • The median follow-up time is 5.0 years, with a range of 2.5-6.7 years.
  • The 1-year estimated probability of freedom from treatment failure was 50% and of survival at 1 year was 92%.
  • Post-treatment specimens were submitted for seven of the 13 patients.
  • Four of the seven converted to Bcl-2 negative following treatment.
  • Eight of 13 Bcl-2 positive patients (62%) had a clinical response to treatment.
  • This study demonstrates that repetitive doses of cyclophosphamide at 4.5 g/m2 every two weeks with rhG-CSF support can be administered to selected younger patients with advanced follicular lymphoma with morphologic involvement of the bone marrow with acceptable non-hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911406.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


12. Ebisui C, Ohkubo K, Akitake H, Ohtsuka M, Yamanaka C, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Fujimoto T: [A case of left inguinal malignant lymphoma occurred after radical operation for gastric cancer and gastrointestinal stromal tumor]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2130-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of left inguinal malignant lymphoma occurred after radical operation for gastric cancer and gastrointestinal stromal tumor].
  • In March 2005, a 70-year-old male patient underwent distal gastrectomy with D2 lymph node dissection for type 3 gastric cancer located in the lower-third of the stomach, and partial gastrectomy for submucosal tumor located in the upper- third of the stomach.
  • Although the adjuvant chemotherapy of S-1 was administered, it was discontinued because of cerebral infarction.
  • Forty months after the operation, CT scan revealed a left inguinal lymph node swelling and recurrence of gastric cancer was doubted.
  • FDG-PET scan confirmed increased uptake only in one lymph node of left inguinal region.
  • In September 2008, left inguinal lymph node dissection was performed and its pathological finding was follicular lymphoma (grade 1).
  • However, it is important to follow-up the patient carefully because the relapse rate of follicular lymphoma is comparatively high.
  • [MeSH-major] Gastrointestinal Stromal Tumors / surgery. Lymphoma, Follicular / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Gastrectomy. Humans. Lymph Node Excision. Male

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037346.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Grupka NL, Seinfeld J, Ryder J, Lillehei KO, Kleinschmidt-Demasters BK: Secondary central nervous system involvement by follicular lymphoma: case report and review of the literature. Surg Neurol; 2006 Jun;65(6):590-4
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary central nervous system involvement by follicular lymphoma: case report and review of the literature.
  • BACKGROUND: We report a patient with indolent stage IV follicular lymphoma, grade 1, initially successfully treated with chemotherapy, who later developed aggressive diffuse large B-cell lymphoma in the parieto-occipital lobe 8 years after initial presentation.
  • The differing patterns of lymphomatous involvement of the central nervous system (CNS) are briefly reviewed, with a focus on the patterns seen in secondary CNS spread by low-grade lymphomas.
  • CASE DESCRIPTION: A 53-year-old man was diagnosed with stage IV follicular lymphoma, grade 1, in 1996.
  • Although initial chemotherapy was successful, he developed several recurrences of lymphoma over the following years.
  • In May 2004, he presented with a discrete, single, massive parieto-occipital lobe brain lesion.
  • The mass proved to be an aggressive diffuse large B-cell lymphoma, transformed from his previous follicular cell lymphoma, with retention of strong Bcl-2 and Bcl-6 immunoreactivity.
  • CONCLUSIONS: Parenchymal brain involvement, as opposed to dural or leptomeningeal, is a relatively uncommon pattern of spread to the CNS for systemic lymphomas.
  • More significantly, follicular lymphomas are one of the least frequent types of indolent lymphomas to develop clinically apparent, secondary CNS spread.
  • The presentation of an indolent follicular lymphoma with transformation to an aggressive diffuse large B-cell lymphoma within the brain parenchyma is rare.
  • Its manifestation as a massive, singular lesion is unique and prompted diagnostic confusion.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / pathology. Occipital Lobe / pathology. Parietal Lobe / pathology
  • [MeSH-minor] Antigens, CD / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720183.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 16
  •  go-up   go-down


14. Niitsu N, Nakamine H, Hayama M, Unno Y, Nakamura S, Horie R, Iwabuchi K, Nakamura N, Miura I, Higashihara M: Ovarian follicular lymphoma: a case report and review of the literature. Ann Hematol; 2002 Nov;81(11):654-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian follicular lymphoma: a case report and review of the literature.
  • Primary ovarian lymphoma is extremely rare, and such a case is reported here.
  • Pelvic CT and MRI showed a right ovarian tumor with a diameter of 7 cm and an irregular border.
  • With the diagnosis of a right ovarian tumor, the patient underwent a simple hysterectomy and bilateral salpingo-oophorectomy.
  • Microscopic examination of the right ovarian tumor revealed vaguely nodular growth of small lymphoid cells.
  • They were CD10+, Bcl-2+, Cyclin D1- and CD21-, although CD21+ follicular dendritic cell clusters were present as a background component in each vague nodule.
  • These findings led us to characterize the lesion as follicular lymphoma, grade 1.
  • The patient was free of detectable disease 9 months after initiation of post-surgical chemotherapy.
  • Since the prognosis for primary ovarian lymphoma is relatively favorable in many cases, it is important to establish therapeutic methods for the cure of this disease using chemotherapy and radiotherapy without radical surgery.
  • [MeSH-major] Lymphoma, Follicular / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Cytogenetic Analysis. Dendritic Cells / pathology. Female. Genes, Immunoglobulin. Humans. Hysterectomy. Middle Aged. Ovariectomy. Remission Induction / methods. Translocation, Genetic


15. Okawa Y, Shimada T, Nagasaki E, Nozato A, Mizoroki F, Kobayashi M: [Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma]. Rinsho Ketsueki; 2006 Jul;47(7):650-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma].
  • We report a case of follicular lymphoma in which pulmonary cryptococcosis occurred with cladribine therapy.
  • He was diagnosed as having follicular lymphoma, grade 1, clinical stage IVA from a tongue tumor biopsy in January 2003.
  • A total of 6 courses of R-CHOP therapy was performed, but no clear effect was found.
  • A new cervical lesion appeared, so he was treated with a total of 2 courses of R-EPOCH therapy, and the effect was classed as stable disease.
  • We started cladribine therapy (0.09 mg/kg, seven days of continuous infusion) from February 2004, and complete remission was achieved after 4 courses of cladribine therapy.
  • In January 2005, an abnormal nodular shadow in the right S10 area was found on chest CT images which was diagnosed as pulmonary cryptococcosis by serum antigen and a trans-bronchial lung biopsy.
  • Afterward, the fifth course of cladribine therapy and local radiation therapy were performed against a relapse of lymphoma, but cryptococcosis did not reappear.
  • The prolonged bone marrow suppression after cladribine therapy was considered to be a severe adverse event.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cladribine / adverse effects. Cryptococcosis / etiology. Lung Diseases, Fungal / etiology. Lymphoma, Follicular / drug therapy. Opportunistic Infections
  • [MeSH-minor] Bone Marrow / drug effects. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cryptococcosis.
  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910576.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


16. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol; 2009 Nov 10;27(32):5404-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
  • Given its efficacy in a wide range of hematologic malignancies, we conducted a phase II trial (NHL-001) of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Patients with relapsed/refractory indolent NHL were eligible, with no limit on the number of previous therapies.
  • Patients received a median of three prior systemic therapies (range, 1 to 17) and half were refractory to last therapy.
  • Twenty-seven percent (six of 22) of patients with follicular lymphoma grade 1 or 2, and 22% (four of 18) with small lymphocytic lymphoma responded to therapy.
  • Adverse events were predictable and manageable; the most common grade 3 or 4 adverse events were neutropenia (30% and 16%, respectively) and thrombocytopenia (14% and 5%, respectively).
  • CONCLUSION: Oral lenalidomide monotherapy produces durable responses with manageable adverse events in patients with relapsed/refractory indolent NHL, warranting further investigation of treatment for indolent NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Constipation / chemically induced. Diarrhea / chemically induced. Drug Administration Schedule. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neutropenia / chemically induced. Recurrence. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


17. Pan D, Qin J, Farber C, O'Brien J, Filippa D, Portlock CS: CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Leuk Lymphoma; 2003 Jun;44(6):967-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
  • The role of high dose therapy, including autologous stem cell transplantation (ASCT) in indolent non-Hodgkin's lymphomas remains controversial.
  • We evaluated a dose intense regimen of CHOP induction followed by high dose cyclophosphamide consolidation (CHOP-HC) versus CHOP alone in a prospective comparison to assess intensified therapy without ASCT.
  • Twenty-five patients with previously untreated advanced stage indolent NHL were enrolled: follicular lymphoma, grade 1 (11 patients) and grade 2 (8 patients); small lymphocytic lymphoma (5 patients); and lymphoplasmacytic lymphoma (1 patient).
  • There were no treatment-related deaths.
  • With no obvious improvement in CR and with greater hematologic toxicity than CHOP, CHOP-HC is not recommended for treatment of indolent non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Rate. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854895.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP protocol, modified
  •  go-up   go-down


18. Mantadakis E, Samonis G: Common symptoms--different diseases: coexistence of neurosyphilis and non-Hodgkin's lymphoma. Infection; 2002 Jan;30(1):43-5
Genetic Alliance. consumer health - Neurosyphilis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common symptoms--different diseases: coexistence of neurosyphilis and non-Hodgkin's lymphoma.
  • We describe the case of a 32-year-old man with generalized lymphadenopathy who was diagnosed with a low-grade follicular small-cleaved cell lymphoma.
  • The patient developed hearing loss, tinnitus and cerebrospinal fluid (CSF) pleocytosis attributed to central nervous system (CNS) infiltration by his malignancy, while receiving chemotherapy with vincristine, cyclophosphamide and prednisone.
  • Despite intrathecal chemotherapy with methotrexate, the CSF pleocytosis persisted.
  • Neurosyphilis was suspected because of prior history of gonorrhea and was confirmed with serologic studies of blood and CSF and from the decline of the anti-treponemal antibody titers with appropriate antibiotic therapy.
  • Syphilis should be considered in the differential diagnosis of patients with generalized lymphadenopathy and neurologic signs or symptoms.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Neurosyphilis / complications. Neurosyphilis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11876517.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, Brown BW, Blume KG: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood; 2001 Jan 15;97(2):404-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.
  • Advanced stage follicular small cleaved and mixed cell lymphoma is characterized by relapse from remission and survival ranging from 6 to 12 years.
  • Because young patients have the greatest compromise in longevity, the efficacy and toxicity of high-dose radiochemotherapy and bone marrow transplantation after conventional chemotherapy was evaluated in a prospective phase II clinical trial.
  • Thirty-seven patients in a minimal disease state after conventional chemotherapy received fractionated total body irradiation and high-dose etoposide and cyclophosphamide, followed by purged autologous bone marrow.
  • Compared with reference patients, transplant recipients had a higher tumor burden at diagnosis.
  • With a median follow-up of 6.5 years, the estimated 10-year survival after transplantation was 86%.
  • There was a single lymphoma death yielding a 10-year disease-specific survival of 97%.
  • High tumor burden at diagnosis and incomplete response to chemotherapy adversely influenced survival in the reference but not in the transplanted patients.
  • The estimated risk of death of 14% and relapse of 30% at 10 years in our transplanted follicular lymphoma patients, the majority of whom had high tumor burdens, compares favorably with our observations in appropriately matched reference patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation / mortality. Lymphoma, Follicular / therapy
  • [MeSH-minor] Actuarial Analysis. Adult. Cohort Studies. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / standards. Cyclophosphamide / toxicity. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Prednisone / administration & dosage. Prednisone / standards. Prednisone / toxicity. Prospective Studies. Radiotherapy, Adjuvant. Recurrence. Remission Induction. Survival Rate. Transplantation, Autologous / mortality. Vincristine / administration & dosage. Vincristine / standards. Vincristine / toxicity

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11154216.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 34233; United States / NCI NIH HHS / CA / CA 49605
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


20. Lasota J, Nordling S, Miettinen M: Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma. Virchows Arch; 2000 Mar;436(3):276-83
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma.
  • Testicular lymphomas usually occur in older men and are mostly diffuse large B-cell lymphomas (DLBL).
  • They may be primary manifestation of lymphoma or represent a relapse of a previous non-Hodgkin's lymphoma.
  • This report details a testicular large cell lymphoma, which was proven to be large cell transformation of a low-grade follicular lymphoma biopsied 8 years earlier.
  • Initially, a 38-year old man was diagnosed with cervical lymphadenopathy, and biopsy was interpreted as reactive follicular hyperplasia; no treatment was given, and the lymphadenopathy resolved spontaneously.
  • The patient died 7 months later with evidence for intra-abdominal and central nervous system lymphoma after a brief but temporary response to M-BACOD chemotherapy.
  • Orchiectomy specimen and gastroscopic biopsy showed diffuse large B-cell lymphoma (CD20+), which infiltrated between well-preserved tubules in the testis.
  • Histological comparison with 20 testicular lymphomas without previous lymphoma showed tubule infiltration in all cases, suggesting that the tubule-preserving infiltration pattern could be a histological marker for secondary lymphoma involvement in testis.
  • On re-examination, the lymph node 8 years prior was verified as follicular, predominantly small, cleaved cell lymphoma with bcl2-positive follicles.
  • The earlier follicular lymphoma and the subsequent diffuse large cell lymphoma were analyzed using polymerase chain reaction and showed identical sequences of the t(14;18) translocation and immunoglobulin heavy chain gene rearrangement.
  • Analysis of the VH-gene sequences from the follicular lymphoma revealed sequence heterogeneity consistent with ongoing mutation.
  • However, the transformed diffuse large cell lymphoma had no intraclonal variation, with the sequence matching with one of the subclones from the low-grade follicular lymphoma.
  • These results confirm that the large cell transformation of follicular lymphoma occurs in a single follicular lymphoma cell.
  • This case also indicates that the selection of the transformed clone can be part of the natural history of disease and can occur without exposure to chemotherapy.
  • [MeSH-major] Cell Transformation, Neoplastic. Genes, Immunoglobulin. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology
  • [MeSH-minor] Base Sequence. Cell Differentiation. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Gene Rearrangement, B-Lymphocyte. Humans. Immunoglobulin Heavy Chains / genetics. Male. Molecular Sequence Data. Polymerase Chain Reaction. Translocation, Genetic

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782887.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


21. Spectre G, Gural A, Amir G, Lossos A, Siegal T, Paltiel O: Central nervous system involvement in indolent lymphomas. Ann Oncol; 2005 Mar;16(3):450-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in indolent lymphomas.
  • BACKGROUND: Central nervous system (CNS) involvement, a well-recognized complication of aggressive non-Hodgkin's lymphomas (NHL), has rarely been reported in indolent lymphomas.
  • PATIENTS AND METHODS: We retrospectively reviewed the disease characteristics and clinical course in seven patients (six females, one male) with indolent B-cell lymphomas who developed CNS involvement during various stages of their illness.
  • RESULTS: The median ages at diagnosis of systemic and CNS lymphoma were 60 and 63 years, respectively.
  • Histologies were: small lymphocytic lymphoma (two), follicular lymphoma grade I (two), follicular lymphoma grade II (two) and unclear low-grade histology (one).
  • Systemic lymphoma was found in all patients, all but one having bone marrow involvement.
  • Four patients had a transformation to high-grade histology.
  • Six patients were treated with systemic and intra-cerebrospinal fluid chemotherapy, and two received radiotherapy as well.
  • CONCLUSIONS: CNS involvement is a rare and unexpected complication of indolent NHL, which should be considered in the differential diagnosis of patients presenting with new neurological signs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642707.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Lee JS, Pei-Lin Ng P, Tao M, Lim WT: Paraneoplastic pemphigus resembling linear IgA bullous dermatosis. Int J Dermatol; 2006 Sep;45(9):1093-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 69-year-old Chinese man presented in 2001 with a blistering eruption over the upper and lower limbs associated with oral ulceration for 1 month.
  • He had stage IIIA follicular small cell cleaved non-Hodgkin's lymphoma diagnosed 5 years previously, and had received several lines of palliative chemotherapy, including two courses of chlorambucil, six cycles of cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP), and two four-cycle courses of rituximab, with disease stabilization at the time of presentation.
  • 4), satellite cell necrosis in the epidermis, and a superficial perivascular infiltrate of lymphocytes and eosinophils.
  • A presumptive diagnosis of paraneoplastic pemphigus was made.
  • Cyclophosphamide was added at a low dose of 1 mg/kg/day as he had baseline leukopenia.
  • He declined rituximab therapy.
  • [MeSH-minor] Aged. China. Diagnosis, Differential. Fatal Outcome. Humans. Male. Skin / immunology. Skin / pathology

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961519.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin A
  •  go-up   go-down


23. Kuruvilla J, Pond G, Tsang R, Gupta V, Lipton JH, Messner HA: Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant; 2008 Jul;14(7):775-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
  • Allogeneic stem cell transplantation (Allo-SCT) remains an option for patients with follicular lymphoma (FL).
  • We performed a retrospective analysis to examine long-term disease control and treatment-related mortality (TRM) in a group of patients that underwent transplant for clinically high-risk disease.
  • Thirty-seven patients with indolent FL (follicular small cleaved [FSC], follicular mixed [FM] or FL grades 1 or 2 by WHO criteria) underwent allo-SCT.
  • Patients were in a chemosensitive remission at the time of SCT.
  • The median age at the time of transplant was 45 years (range: 24-58).
  • The median number of prior chemotherapy regimens was 3 (range: 1-6).
  • With a median follow-up of 63.5 months in survivors, the 5-year overall survival is 79.1% (95% confidence interval 66.3%-94.4%).
  • These results demonstrate that in selected younger patients, a fully myeloablative allo-SCT utilizing BuCy conditioning provides excellent OS and disease control with low TRM.
  • [MeSH-major] Graft vs Tumor Effect. Lymphoma, Follicular / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Age Factors. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Salvage Therapy / methods. Transplantation, Autologous

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541196.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Alduaij A, Hansen K, Zhang C: Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report. Diagn Pathol; 2010;5:44
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report.
  • We report a rare case of primary lymphoma of fallopian tube in a 68-year-old woman who underwent total hysterectomy and bilateral salpingo-oophorectomy for endometrial carcinoma.
  • The specimen showed a well-differentiated endometrioid adenocarcinoma with superficial myometrial invasion.
  • The left fallopian tube revealed a 1 cm nodule that histologically showed diffuse lymphoid follicles consisting of small cleaved lymphocytes and occasional larger cells.
  • Polymerase chain reaction confirmed a monoclonal B-cell population.
  • The findings were consistent with a primary low grade follicular lymphoma of fallopian tube.
  • She did not receive chemotherapy and remained disease free for 13 months after surgery.
  • Our case suggests that primary lymphoma of fallopian tube may be associated with a favorable prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / pathology. Hysterectomy. Incidental Findings. Lymphoma, Follicular / pathology. Neoplasms, Multiple Primary. Ovariectomy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Intraoperative Period. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):384-6 [12217767.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1933-43 [6627208.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jan;25(1):1-21 [16306779.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(4):394-401 [1774110.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):736-8 [15581994.001]
  • [Cites] Pathol Annu. 1991;26 Pt 1:227-63 [2014141.001]
  • (PMID = 20584306.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2905343
  •  go-up   go-down


25. Cohen Y, Amir G, Polliack A: Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma. Eur J Haematol; 2002 Feb;68(2):117-9
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma.
  • This report deals with an unusual case of a patient with follicular small cleaved lymphocytic lymphoma who developed Merkel-cell carcinoma soon after receiving chemoimmunotherapy with a fludarabine-containing regimen and rituximab.
  • The presentation of the Merkel-cell carcinoma in this patient was atypical because of the absence of dermal involvement and the very rapid clinical progression.
  • In the light of recent reports which suggest a possible link between the immunocompromised state and the development of Merkel-cell carcinoma, the atypical presentation seen in this patient may indeed imply a possible link between the therapy given and the development of Merkel-cell carcinoma.
  • To the best of our knowledge, this is the first documentation of Merkel-cell carcinoma appearing in a patient soon after treatment with fludarabine and/or rituximab.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Merkel Cell / etiology. Lymphoma, Follicular / drug therapy. Vidarabine / adverse effects
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Humans. Male. Middle Aged. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / pathology. Recurrence. Rituximab. Salvage Therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12061321.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


26. Lorusso V, Palmieri G, Bianco AR, Abate G, Catalano G, De Vita F, Dammacco F, Lauta VM, Lucarelli G, Polimeno G, Mantovani G, D'Aprile M, Marzullo F, De Lena M: CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol; 2000 Jan;16(1):149-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
  • From January 1992 to December 1995, 129 patients with previously untreated non-Hodgkin's lymphoma were randomised in a phase III multicenter trial to receive CEOP-B/VIMB or ProMACE-CytaBOM.
  • Eligibility criteria included intermediate or high grade lymphoma (follicular large cell, diffuse small cleaved-cell, diffuse mixed, diffuse large-cell and immunoblastic) with an Ann Arbor stage II bulky, III or IV.
  • At a median follow-up of 60 months there were no significant differences between the treatment response rates [82% (60%CR) for CEOP-B/VIMB vs. 81% (69% CR) for ProMACE-CytaBOM].
  • Conversely, with regard to disease-free survival, a significant difference was observed between the two treatment arms (42% for CEOP-B/VIMB vs. 24% for ProMACE-CytaBOM at 5 years; p=0.046).
  • Moreover, when response rates and outcome were analysed for different prognostic subgroups according to International Prognostic Index, no significant differences were observed between the treatment groups.
  • It is important to note that neither regimen was able to improve outcome of poor risk patients who fared badly with both treatments (median survival 9 and 8 months respectively).
  • Toxicity was also similar in both treatments with grade 3-4 leukopenia observed in 39% and 47% of cases and grade 3-4 thrombocytopenia in 24% and 27% of cases respectively.
  • In conclusion, in this study CEOP-B/VIMB was not superior to ProMACE-CytaBOM in aggressive lymphomas and the alternating strategy failed to improve outcome of poor risk patients in which newer more aggressive treatments are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10601560.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CEOP-B protocol; PROMACE-CytaBOM protocol
  •  go-up   go-down


27. Abdelkefi A, Mellouli F, Béjaoui M: Treatment of a patient with chronic renal failure with rituximab for a follicular lymphoma: safe and successful option of rituximab therapy. Eur J Haematol; 2003 Aug;71(2):128-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of a patient with chronic renal failure with rituximab for a follicular lymphoma: safe and successful option of rituximab therapy.
  • A 47-yr-old woman presented a chronic renal failure for 5 yr, with a creatinine clearance of 12 mL/min.
  • In June 2002, she had a right axillary lymph node (of 4 cm diameter).
  • A biopsy revealed a follicular lymphoma (histology: follicular small cleaved-cell).
  • She had Ann Arbor stage III disease, with a high tumor burden according to the GELF criteria.
  • She received rituximab as single first-line treatment (375 mg/m2 by intravenous infusion for a total of four dosages: days 1, 8, 15 and 22).
  • Rituximab therapy was extremely well tolerated, and we obtained a partial response, 4 wk after completing the treatment.
  • Six weeks after maintenance therapy, a complete response was achieved.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Kidney Failure, Chronic / complications. Lymphoma, Follicular / complications. Lymphoma, Follicular / drug therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12890153.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


28. Tulpule A, Rarick MU, Kolitz J, Bernstein J, Myers A, Buchanan LA, Espina BM, Traynor A, Letzer J, Justice GR, McDonald D, Roberts L, Boswell W, Nathwani B, Levine AM: Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol; 2001 Apr;12(4):457-62
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma.
  • PURPOSE: To assess the efficacy and toxicity of liposomal daunorubicin administered as a two-hour intravenous infusion to patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Eligible patients had relapsed or refractory NHL with measurable or evaluable disease, and low grade, select intermediate grade, or mantle cell pathologic types.
  • Liposomal daunorubicin at a dose of 100 mg/m2 was given intravenously over a minimum of 120 minutes every 3 weeks. as a single agent.
  • RESULTS: Thirty-three patients were accrued: twenty-three (70%) had low-grade histologies; six (18%) had intermediate-grade histologies (follicular large-cell and diffuse small cleaved); and four (12%) patients had mantle-cell lymphoma.
  • Six responders (50%) had received a prior anthracycline; one responder had mantle-cell histology.
  • The major toxicities were grade 3 or 4 neutropenia in 26 patients (79%), mild to moderate nausea in 22 (67%), and fatigue in 16 (48%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2001 Apr;12(4):433-4 [11398872.001]
  • (PMID = 11398876.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down






Advertisement